In oncology drug development, the maxim “more is better” has long guided dose-selection studies. Sponsors habitually used simple, rule-based designs for dose selection, initially developed to establish the maximum tolerable dose (MTD) for chemotherapeutic agents. However, the MTD is increasingly seen as suboptimal for targeted and immunotherapies, which lack chemotherapy’s generalised cytotoxic effects. These therapies may have a benign toxicity profile with a dose lower than the MTD, providing the highest level of efficacy.
More contemporary dose-selection designs can now identify the lowest dose of an oncology therapy with the highest rate of efficacy that is tolerable for patients — commonly referred to as the optimal biological dose (OBD). These alternative designs are increasingly required by regulators, who expect sponsors to move away from long-entrenched, dose-selection paradigms and instead identify their drug’s optimal dose. To facilitate the shift to OBD-based dose selection, the U.S. Food and Drug Administration launched Project Optimus in 2021.
However, many companies are struggling to adjust to more stringent dose-selection requirements. Diverse dose-selection designs are available, with varied approaches to balancing participant safety, accurate dose selection, and simplicity. Transitioning from simple, rule-based designs to more complex model-based or model-assisted designs requires support and specialised expertise.
CRO partners, such as ICON plc, can assist sponsors in selecting and implementing cost-effective and efficient dose-selection designs based on a drug’s characteristics and study objectives. For example, ICON provided expert consultation, including model simulation, during the early-phase clinical trial of a tri-specific antibody targeting multiple tumor types.
ICON successfully implemented Bayesian designs in a two-part, first-in-human trial that assessed drug safety and toxicity, and then preliminary efficacy in cohorts of patients with different tumor types.
In the first part of the trial, a Bayesian Optimal Interval (BOIN) design was selected for its relative statistical simplicity and intuitiveness to investigators. However, it soon became clear that toxicity did not increase monotonically with dose. ICON then modified the BOIN design to maximise the use of pharmacodynamic information to help select the optimal dose without increasing patient numbers, costs, or study timelines.
Subsequently, a Bayesian Optimal Phase II design was selected for dose-expansion in single-arm patient cohorts with different tumor types because it allowed for efficient monitoring of clinical activity, and resulted in the most efficient sample size. The design was then amended to include a cohort with a control arm using a Bayesian logistic regression model.
For drugs known to have a benign safety profile, alternative designs that explore safety and efficacy simultaneously — such as BOIN 12 or TITE-BOIN 12 — should be considered. Additionally, early-phase oncology studies may benefit from deploying Bayesian basket designs to efficiently investigate efficacy in patients with different types of cancer.
As oncology therapeutics and early-phase design models evolve, sponsors will benefit from partnering with a company experienced in innovative designs for phase I and II oncology trials.
To learn more about dose optimisation and dose selection for oncology therapeutics, please contact us.
This article was first published on Clinical Oncology Daily on 3 June 2024.
In this section
-
Digital Disruption
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
-
Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Flexible delivery models
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel